India Oncology Market Report : Industry Size, Share, Demand, Growth & Forecast 2026-2034

According to the latest research report titled "India Oncology Market Size, Share, Trends and Forecast by Cancer Diagnostics and Treatment, Cancer Type, End Use, and Region, 2026-2034," the report provides a comprehensive analysis of the market's growth potential, emerging trends, and competitive landscape shaping the industry.

How Big is the India Oncology Market?

The India oncology market size was valued at USD 11.73 Billion in 2025 and is projected to reach USD 30.01 Billion by 2034, growing at a compound annual growth rate (CAGR) of 10.45% during the forecast period 2026-2034. The market growth is driven by the increasing incidence of cancer, improving healthcare infrastructure, adoption of innovative technologies, government initiatives in the healthcare sector, expanding insurance coverage, and investments in personalized medicine improving the accessibility and affordability of treatments.

Evaluate Market Opportunity with the Business Sample Report: https://www.imarcgroup.com/india-oncology-market/requestsample

What are the Latest Emerging Trends in India Oncology Market?

Rising Adoption of Precision Medicine and Targeted Therapies

India's oncology landscape is witnessing a significant shift toward precision medicine, with growing utilization of genomic profiling and biomarker-driven treatment approaches. In February 2026, Metropolis Healthcare Limited unveiled its new Centre of Genomics and hosted a multi-specialty genomics symposium aimed at accelerating the adoption of advanced genomic diagnostics to inform personalized cancer care pathways across India. Healthcare providers are increasingly adopting targeted therapies and antibody-drug conjugates that offer improved efficacy and reduced side effects compared to conventional treatments, expanding personalized care options for patients with specific cancer mutations.

Expansion of Digital Health and AI-Driven Cancer Diagnostics
Artificial intelligence and digital health technologies are increasingly being integrated into cancer diagnostics and treatment planning across India. In August 2025, diagnostics leader Dr. Lal PathLabs introduced a deep learning-based AI module to detect lymph node metastasis across multiple cancer types, helping identify spread earlier and with higher accuracy in clinical workflows. AI-powered pathology tools, imaging analysis systems, and telemedicine platforms are improving early cancer detection and enhancing clinical decision-making, particularly bridging healthcare access gaps between urban and rural regions.

Growth of Biosimilars and Affordable Oncology Drug Development

The expanding availability of biosimilar oncology drugs is transforming treatment accessibility in India by offering cost-effective alternatives to expensive biologic therapies. In September 2025, Alkem Laboratories launched Pertuza, a pertuzumab biosimilar for HER2-positive breast cancer in India, developed indigenously to expand access to a critical targeted therapy at lower cost. Domestic pharmaceutical companies are actively developing and launching biosimilar versions of key oncology biologics, supported by favorable regulatory pathways and growing physician confidence in biosimilar efficacy, enabling wider adoption of advanced cancer treatments across diverse patient populations.

What Growth Factors are Driving India Oncology Market?

Rising Cancer Incidence and Growing Disease Burden
India is witnessing an increasing trend in cancer incidence due to demographic changes including aging and urbanization. According to recent findings from the Indian Council of Medical Research (ICMR), India recorded around 14.6 lakh new cancer cases in 2022, with one in nine people now estimated to be at lifetime risk of developing cancer, underscoring the growing burden driven by lifestyle and environmental factors. Use of tobacco, changes in food habits, sedentary lifestyles, rising obesity, and pollution are contributing to the rising incidence of different types of cancer, creating sustained demand for comprehensive cancer care solutions across all categories of the healthcare system.

Expanding Government Health Programs and Policy Support

The Indian government is playing a crucial role in improving cancer care infrastructure through specific health programs, financial support, and policy changes. In February 2026, the Haryana government inaugurated 22 day-care cancer centres across 17 districts to provide free chemotherapy, follow-up treatment, and supportive care locally, reducing travel burdens and out-of-pocket expenses for patients. National health insurance schemes covering cancer treatment costs for economically vulnerable sections, programs related to early detection and screening, and customs duty exemptions on essential cancer drugs are collectively making cancer treatment more accessible and affordable across urban and rural areas.

Advancements in Treatment Technologies and Drug Innovation

The emergence of innovative technologies in cancer treatment is rapidly transforming India's oncology landscape, with the launch of new immunotherapies, targeted therapies, antibody-drug conjugates, and cell therapies offering more treatment options to physicians. Indian regulators have recently cleared a range of precision oncology treatments including immunotherapies and antibody-drug conjugates, driving broader access to advanced targeted therapies and accelerating the shift toward personalized care. The development of domestic gene therapies, extension of biosimilar portfolios in oncology, and adoption of advanced surgical technologies such as robotic surgery are further improving treatment outcomes.

How Will the India Oncology Market Evolve in the Coming Years?

The India oncology market is set for sustained growth, driven by continuous advancements in healthcare infrastructure, rising government investments in cancer care, and increasing adoption of innovative treatment modalities. Expanding insurance coverage, growing emphasis on early diagnosis, and the establishment of specialized oncology centres are expected to further accelerate market expansion. The integration of precision medicine, development of affordable biosimilar therapies, and strengthening of public health programs focused on cancer prevention and screening are creating a more supportive environment for long-term market development.

With the market projected to grow from USD 11.73 Billion in 2025 to USD 30.01 Billion by 2034, the industry will benefit from the increasing development of domestic gene therapies and biosimilar portfolios, expansion of AI-driven diagnostics and digital health platforms, growing public-private partnerships improving cancer care infrastructure, and India's strengthening position as an emerging destination for cancer research, clinical trials, and oncology innovation.

India Oncology Market Segmentation

Cancer Diagnostics and Treatment

• Cancer Diagnostics: Includes tumor biomarkers tests, imaging, biopsy, liquid biopsy, immunohistochemistry, and in situ hybridization, with growing adoption of AI-driven and genomic diagnostic tools enabling earlier and more accurate cancer detection across diverse clinical settings.

• Cancer Treatment: Dominates with a 64.9% share in 2025, encompassing chemotherapy, targeted therapy, immunotherapy, hormonal therapy, and emerging cell-based approaches, driven by expanding treatment capabilities, rising drug affordability, and government financial assistance for cancer care.

Cancer Type

• Lung Cancer: Leads with an 18.7% market share in 2025, driven by high tobacco use prevalence, rising air pollution exposure, growing screening access, and expanding targeted therapy and immunotherapy options for specific genetic mutations and advanced-stage disease.

• Prostate Cancer: Growing segment driven by increasing disease awareness, expanding PSA screening programs, and rising adoption of hormone therapies and targeted treatments.

• Colon and Rectal Cancer: Significant segment reflecting dietary and lifestyle shifts, with growing endoscopic screening and targeted therapy adoption.

• Gastric Cancer: Important segment driven by high prevalence in specific demographic groups and expanding multimodal treatment approaches.

• Esophageal Cancer: Driven by tobacco and alcohol consumption patterns, with increasing access to surgical and oncological interventions.

• Liver Cancer: Growing segment linked to high hepatitis B and C prevalence, with expanding treatment access through targeted and immunotherapy options.

• Breast Cancer: Significant segment with expanding screening programs, growing biosimilar availability for HER2-positive disease, and strong awareness campaigns.

• Others: Includes cervical, ovarian, hematological, and other cancer types benefiting from expanding diagnostic and therapeutic capabilities.

End Use

• Hospitals: Dominate with a 53.6% share in 2025, serving as the primary centres for cancer diagnosis, treatment, and long-term patient management, with concentration of multidisciplinary teams, advanced surgical capabilities, radiation therapy equipment, and comprehensive diagnostic services.

• Diagnostic Laboratories: Important segment driven by growing demand for molecular testing, biomarker analysis, liquid biopsy, and genomic profiling supporting precision oncology.

• Diagnostic Imaging Centers: Expanding segment benefiting from rising adoption of advanced imaging modalities including PET-CT, MRI, and AI-enhanced radiology for cancer detection and staging.

• Academia: Contributing to oncology research, clinical trials, and the development of novel diagnostic and therapeutic approaches.

• Specialty Clinics: Growing segment offering focused oncology care, outpatient chemotherapy, and supportive services complementing hospital-based treatment.

• Others: Includes home care agencies and other ancillary cancer care service providers.

Regional Insights

• North India: Significant market driven by high patient volumes across major states, concentration of tertiary cancer centres in Delhi and NCR, active government expansion of district-level cancer care facilities, and Haryana's inauguration of 22 day-care cancer centres supporting accessible chemotherapy services.

• South India: Rapidly growing market supported by advanced cancer care infrastructure in Bengaluru, Chennai, Hyderabad, and Kochi, growing adoption of robotic surgery and precision oncology, and expanding medical tourism for cancer treatment from neighboring regions and countries.

• East India: Emerging market with growing government investment in cancer care infrastructure, expanding diagnostic capabilities in Kolkata and other urban centers, and increasing adoption of telemedicine and AI tools bridging access gaps in underserved areas.

• West India: Dominant region with a 32.4% share in 2025, driven by premier cancer treatment institutions, advanced healthcare infrastructure, higher healthcare expenditure, significant pharmaceutical and biotechnology industry presence engaged in oncology research, and growing medical tourism for complex cancer procedures.

The dominant regions collectively contribute to India's growing stature as an important oncology market in Asia. The market is expected to grow at a 10.45% CAGR driven by rising cancer incidence, expanding treatment access, advancing precision medicine adoption, and government-backed healthcare infrastructure development.

Recent Developments & News

• January 2026: Zydus Lifesciences launched Tishtha, the world's first biosimilar of the immuno-oncology drug nivolumab in India to treat multiple cancers, at about one-fourth the cost of the original, aiming to expand access and significantly reduce the treatment burden for patients requiring immunotherapy across diverse cancer indications.

Competitive Landscape:

The report offers an in-depth examination of the competitive landscape, including market structure, key player positioning, leading strategies for success, a competitive dashboard, and a company evaluation quadrant.

Key Highlights of the Report

• Comprehensive quantitative analysis of historical and current market trends

• Detailed segment-wise market assessment by cancer diagnostics and treatment, cancer type, end use, and region

• Market growth drivers, challenges, and opportunities analyzed thoroughly

• Porter's Five Forces analysis to assess competitive rivalry and market attractiveness

• Competitive landscape overview with positioning and strategies of key market players

Get Custom Report Based on Your Interest: https://www.imarcgroup.com/request?type=report&id=45268&flag=E

Customization Note

If you require any specific information not covered within the report's scope, it will be provided as part of the customization.

Frequently Asked Questions (FAQs)

Q1. What is the size of the India oncology market?

A. The India oncology market size was valued at USD 11.73 Billion in 2025.

Q2. What is the expected growth rate of the market?

A. The market is projected to grow at a CAGR of 10.45% from 2026-2034, reaching USD 30.01 Billion by 2034.

Q3. What factors are driving the growth of the market?

A. Key factors include rising cancer incidence driven by tobacco use, lifestyle changes, aging demographics, and environmental carcinogens creating sustained demand for oncology solutions, expanding government health programs and insurance coverage improving treatment accessibility, advancements in treatment technologies including immunotherapy, targeted therapies, and biosimilars broadening patient access, and growing adoption of precision medicine and AI-driven diagnostics transforming cancer care pathways across India.

Q4. Which segment dominates the India oncology market?

A. Cancer treatment dominates the cancer diagnostics and treatment segment with a 64.9% share in 2025. Lung cancer leads by cancer type at 18.7%, hospitals dominate the end-use segment at 53.6%, and West India leads regionally with a 32.4% share driven by premier cancer care institutions and advanced healthcare infrastructure.

Q5. What are the major challenges facing the India oncology market?

A. Major challenges include high costs of advanced cancer treatments including immunotherapies and cell-based therapies creating financial hardship for a large proportion of patients, significant disparities in healthcare infrastructure between urban and rural areas compelling patients to travel long distances for care, late-stage cancer diagnosis driven by limited screening programs and cultural barriers delaying timely intervention, and inadequate availability of trained oncology specialists and treatment facilities across tier-2, tier-3, and rural healthcare settings.

Get Sample of Our Latest In-Depth Reports On Related Topics:

India Data Center Server Market: https://www.imarcgroup.com/india-data-center-server-market/requestsample

India Jewellery Market: https://www.imarcgroup.com/india-jewellery-market/requestsample

India Medical Tubing Market: https://www.imarcgroup.com/india-medical-tubing-market/requestsample

India Nutraceuticals Market: https://www.imarcgroup.com/india-nutraceuticals-market/requestsample

IMARC Group

134 N 4th St. Brooklyn, NY 11249, USA
Email: sales@imarcgroup.com
Tel: (D) +91 120 433 0800
United States: +1-201-971-6302

IMARC Group is a global management consulting firm that helps ambitious changemakers create a lasting impact. The company offers comprehensive market assessment, feasibility studies, incorporation support, regulatory assistance, branding and strategy services, and procurement research.

This release was published on openPR.